MERRIMACK PHARMACEUTICALS IN (MACK) Stock News
NASDAQ:MACK - Nasdaq - US5903282094 - Common Stock - Currency: USD
MACK Latest News, Press Relases and Analysis
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024
Merrimack Pharmaceuticals just reported results for the first quarter of 2024.
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023
Merrimack Pharmaceuticals just reported results for the fourth quarter of 2023.
Merrimack Receives $225 Million Milestone Payment from Ipsen
Merrimack Reports Full Year 2023 Financial Results
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
Pancreatic Cancer Battle Boosted by $200M VC Firm
/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Reports Second Quarter 2023 Financial Results
Merrimack Reports First Quarter 2023 Financial Results
3 Stocks Insiders Are Buying: Triumph Financial And More
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
Upstart (UPST) Stock Sinks on Gloomy Forecast
Upstart (UPST) stock is sliding lower on Wednesday following a poor performance in the third quarter of 2022 and a weak outlook.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning!
Merrimack Reports Full Year 2022 Financial Results
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...